~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences,...
~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~
~ Additional Funding from Investor Cohort Validates Company's Mission ~
SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...
SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve...
- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT
~ Nasal Opioid Abuse Being Explored for PF614 ~
Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage...
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.